Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

BACKGROUND

It is intuitively thought that early relapse is associated with poor survival after recurrence (SAR) in resected colon cancer (CC) patients, but this has never been formally studied.

METHODS

We pooled data from stage III patients treated with oxaliplatin-based adjuvant therapy in two phase III trials, to analyse time to recurrence (TTR) and its relationship with SAR. TTR and SAR were also studied according to molecular status (mismatch repair (MMR), RAS, and BRAF

RESULTS

4548 stage III CC patients were included in the present analysis. Deficient MMR (dMMR) CC patients experienced fewer recurrences than proficient (p)MMR CC patients (18.8% versus 27.6%) but had a significantly shorter median TTR (mTTR; 0.74 versus 1.40 years, p < 0.0001). In pMMR patients, BRAF and RAS mutations were also associated with earlier mTTR as compared to double wild-type (WT) patients (0.99 versus 1.38 versus 1.54 years, respectively, p < 0.0001). Early recurrence occurred in 397 patients and was associated with a median SAR (2.2 versus 3.3 years, p = 0.0007). However, this association was mainly due to pMMR/RAS and BRAF

CONCLUSION

In resected stage III CC treated with standard oxaliplatin-based adjuvant therapy, TTR varies between dMMR, pMMR/RAS, or BRAF

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest JT has received honoraria as a speaker or in an advisory role from Sanofi, Roche, Merck Serono, Amgen, Servier, Pierre Fabre, Lilly, AstraZeneca, and MSD. PLP has received honoraria as a speaker or in an advisory role from ESMO, Amgen, Servier, Pierre Fabre, Biocartis, and stocks from Methys DX. SL has received honoraria as an invited speaker from Roche, Eli Lilly, Bristol Myers Squibb, Servier, Merck Serono, Pierre Fabre, GlaxoSmithKline, Amgen, and has participated in an advisory board for Amgen, Merck Serono, Eli Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, Bristol Myers Squibb, Servier, and Merck Sharp & Dohme. TA has attended advisory board meetings and received consulting fees from AstraZeneca, Astellas, Aptitude Health, Bristol Myers Squibb, Gritstone Oncology, GamaMabs Pharma SA, Gilead, GlaxoSmithKline, Merck & Co. Inc., Nordic Oncology, Pierre Fabre, Seagen, Servier and Transgene; has received honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck & Co. Inc., Merck Serono, Pierre Fabre, Roche, Sanofi, Seagen and Servier; and has received support for meetings from Merck & Co. Inc., and Servier. CL was a consultant and had an advisory role for Novartis and AAA, and has received speaker honoraria from AMGEN, and Bayer. OB has received honoraria as a speaker and in an advisory role from Merck Serono, Amgen, Bayer, Servier, Pierre Fabre, Deciphera, Apmonia Therapeutics, and MSD. AL has received honoraria as a consultant and speaker from Advance Accelerator Applications, Amgen, Bayer, F. Hofmann-La Roche, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Mylan Pharmaceuticals Inc, Novartis, Pierre Fabre Pharmaceuticals Inc, Sandoz, Sanofi Pasteur Inc and has received research grants from Bayer and Lilly Deutschland. CLO reports personal fees and non-financial support from Merck, Roche; personal fees from Servier; and personal fees from Amgen outside the submitted work. JBB has received personal fees from Amgen, Bayer, Bristol Myers Squibb, Merck Serono, Merck Sharp & Dohme, Pierre Fabre, Sanofi, Servier, and non-financial support from Amgen, Merck Serono, and Roche, outside the submitted work. JB is involved as an advisory board member for AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Ipsen, Servier, and Sanofi and has received honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Merck, MSD, Daiichi, Servier, Ipsen, Jansen, and Sanofi. CB has received honoraria as a consultant from Bayer, Molecular Partners, MSD, Pierre Fabre, and Servier, and has received research grants from Bayer, Roche, and Boehringer. All remaining authors have declared no conflicts of interest.